RxDoctor Payments Data

Ruben Cabral, MD

Internal Medicine · Fullerton, CANPI 1568458008

Payments from drug & device makers

$2,120in general payments, 2019–2025

Across 116 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$437
  • Amgen$373
  • Pfizer$241
  • Novo Nordisk$240
  • AbbVie$234
  • Lilly USA, LLC$177
  • plus $419 from 9 others

What the payments were for

  • Consulting fees$201%
  • Food & beverage$1,84687%
  • Education$25412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,120 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$246,904
Medicare patients
519
Services billed
7,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban382$330,171
OzempicSemaglutide284$282,194
TrulicityDulaglutide178$241,353
JardianceEmpagliflozin177$188,283
JanuviaSitagliptin Phosphate101$103,126
XareltoRivaroxaban84$102,835
MounjaroTirzepatide95$99,135
CreonLipase/Protease/Amylase24$95,514
MyrbetriqMirabegron58$38,662
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog48$37,886
Breo ElliptaFluticasone/Vilanterol44$34,486
LinzessLinaclotide41$32,792
EntrestoSacubitril/Valsartan23$28,920
Duloxetine Hcl526$25,534
InvokanaCanagliflozin13$21,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$241$343,213417 claims
Lilly USA, LLCTrulicity, Mounjaro$177$340,488273 claims
Novo NordiskOzempic$240$282,194284 claims
Boehringer IngelheimJardiance, Tradjenta$39$203,904190 claims
AbbVieCreon, Linzess, Synthroid$234$133,283154 claims
MerckJanuvia, Janumet, Janumet Xr$42$132,581134 claims
GSKBreo Ellipta, Trelegy Ellipta$149$49,91567 claims
Astellas Pharma US IncMyrbetriq$437$38,66258 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fullerton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →